Skip to main content

Table 1 mTOQ-4 total score at baseline and week 4 by baseline acute treatment optimization subgroup

From: Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study

   Eptinezumab 100 mg Placebo
Optimization subgroup Time point Mean (SD) [n] Mean (SD) [n]
 Very poor Baseline 11.2 (2.4) [25] 11.6 (2.2) [25]
Week 4 16.2 (5.3) [25] 13.9 (5.5) [24]
Change from baseline 4.9 (4.9) [25] 2.4 (5.1) [24]
 Poor Baseline 17.0 (2.6) [138] 16.8 (2.7) [117]
Week 4 19.6 (4.1) [130] 18.4 (3.3) [114]
Change from baseline 2.5 (4.2) [130] 1.5 (3.0) [114]
 Moderate Baseline 21.5 (1.2) [46] 21.9 (1.0) [65]
Week 4 22.1 (2.1) [44] 22.2 (2.0) [63]
Change from baseline 0.6 (2.0) [44] 0.3 (1.8) [63]
 Maximal Baseline 23.8 (0.5) [28] 23.8 (0.5) [35]
Week 4 23.1 (1.8) [26] 23.2 (2.0) [30]
Change from baseline -0.7 (1.9) [26] -0.7 (2.0) [30]
Simplified subgroups
 Poorly optimized Baseline 16.1 (3.3) [163] 15.9 (3.3) [142]
Week 4 19.0 (4.5) [155] 17.6 (4.1) [138]
Change from baseline 2.9 (4.4) [155] 1.7 (3.5) [138]
 Optimized Baseline 22.4 (1.5) [75] 22.6 (1.2) [100]
Week 4 22.5 (2.0) [71] 22.6 (2.0) [93]
Change from baseline 0.1 (2.1) [71] 0.0 (1.9) [93]
  1. Patients were grouped by baseline mTOQ-4 total scores into the following optimization categories: very poor (0), poor (1–5), moderate (6–7), and maximal (8). Simplified subgroups consist of patients with mTOQ-4 total scores in very poor (0) and poor (1–5) categories together, along with patients with total scores in the moderate (6–7) and maximal (8) categories grouped together. Epti, eptinezumab (100 mg); mTOQ-4/mTOQ-6, 4-item/6-item Migraine Treatment Optimization Questionnaire